Cost-Utility Analysis of Melphalan plus Prednisone With or Without Interferon-α2b in Newly Diagnosed Multiple Myeloma

This publication has 23 references indexed in Scilit:

• Effect of interferon on the health‐related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan–prednisone to melphalan–prednisone + α‐interferon
  British Journal of Haematology, 1996
• The friction cost method for measuring indirect costs of disease
  Journal of Health Economics, 1995
• The trade-off between severity of illness and treatment effect in cost-value analysis of health care
  Health Policy, 1993
• The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
  JNCI Journal of the National Cancer Institute, 1993
• Toward Quality Assurance in QALY Calculations
  International Journal of Technology Assessment in Health Care, 1993
• Cost-utility in practice: A policy maker's guide to the state of the art
  Health Policy, 1992
• Has the incidence of multiple myeloma in old age been underestimated?
  European Journal of Haematology, 1991
• EuroQol - a new facility for the measurement of health-related quality of life
  Health Policy, 1990
• The economics of hypertension and stroke
  American Heart Journal, 1990
• Comparison of Trends in the Incidence of Multiple Myeloma in Malmö, Sweden, and Other Countries, 1950–1979
  New England Journal of Medicine, 1984